News:
LA4. SUMO in cancer
Modifications of the proteins play key roles in controlling protein activity and hence cell function. This is mainly due to their ability to rapidl...
» more
|
|
|
News:
LA2. - Die Happy? – Live Longer? Or how to mani...
|
|
Agnes van Rossum, Karin Hek, Henk Vietor, and Ger Strous
UMC Utrecht in collaboration with DDF BV, Bussum, The Netherlands
A major topic in tod...
» more
|
|
|
News:
PR2 08.08.13: THE DAILY TELEGRAPH: Dementia stu...
|
|
THE DAILY TELEGRAPH refers to a recent paper published by Professor John Mayer and collaborators in The Jour...
» more
|
|
|
News:
C1a: 2009, September 22-26, EMBO Conference: Ub...
|
|
We would like to announce the EMBO Conference on Ubiquitin and Ubiquitin-like Modifiers in Health and Disease. This conference is part of a series...
» more
|
|
|
Participant:
Alain Israël's Group
The group focuses on the analysis of two signaling pathways : NF-kappaB and Notch. More specifically, ex vivo approaches based on biochemical and g...
» more
|
|
|
Participant:
CYTOMICS SYSTEMS
CYTOMICS SYSTEMS’ protein degradation approach to drug discovery relies on UbiScreen®, a patented functional screening technology relevant to all t...
» more
|
|
|
Participant:
DDF Research Group
DDF is involved in several drug discovery programs including finding new cures for prostate cancer, dendritic based cancer vaccines, osteoporosis a...
» more
|
|
|
Participant:
Anne Dejean's Group
|
|
The group is centered on the study of molecular and cellular mechanisms leading to human cancers with a particular emphasis on the role of certain...
» more
|
|
|
Participant:
Frauke Melchior's Group
|
|
Participant:
SME: Proteologics
Proteologics is a biopharmaceutical company comprising bio- and chemi-informatics, target discovery, target validation, assay development and drug...
» more
|
|
